Keeping fit, even if you’re born with a high genetic risk for heart disease, still works to keep your heart healthy, according to a new study.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
23andMe CEO and co-founder Anne Wojcicki says consumers don’t need experts to interpret results from genetic risk tests, and compared the information her company offers to at-home pregnancy tests. But is it that simple?
Use of one of a cancer treatment offered on the basis of biomarkers instead of tissue type is being restricted because of inaccurate, insensitive diagnostic tests.
There is, as of yet, no cure for Alzheimer’s, but a new blood test could open the door to new avenues in drug discovery.
Critically ill infants in the Australian state of Victoria are now to be given access to rapid genomic sequencing under a new government-funded programme.
Even though the $550 yellow pills sold as Korlym have a controversial origin as the abortion pill, Leslie Edwin said they “gave me life.”
Patient advocacy groups take in millions from drugmakers. Is there a payback? Kaiser Health News launches “Pre$cription for Power,” a groundbreaking database to expose Big Pharma’s ties to patient groups.
New findings suggest that many senior citizens remain more cognitively and emotionally intact than commonly believed. This could perhaps provide clues as to how we can keep our minds sharper for longer.
Studies carried out at Emory University have shown that DNA methylation patterns in saliva appear to be more similar to patterns from the brain, than methylation in blood. Researcher Alicia Smith Associate Professor and Vice Chair for Research, Gynecology and Obstetrics at Emory University joins the discussion.
Dr Joan O’Brien, chair of the University of Pennsylvania’s Department of Ophthalmology, Scheie Eye Institute, Philadelphia, and primary investigator of POAAGG, joins our panel of experts on April 10th to discuss bias in genetic studies and what is being done to remove it.
Access to electronic patient data has huge potential, and with the federal Centers for Medicare and Medicaid Services calling for entry, we could soon be seeing the impact in the healthcare system.